Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients

European Journal of Endocrinology

Volumn 165, Issue 3, 2011, Pages 441-446

  Castagna, Maria Grazia ^a   Maino, Fabio ^a   Cipri, Claudia ^a   Belardini, Valentina ^a   Theodoropoulou, Alexandra ^a   Cevenini, Gabriele ^a   Pacini, Furio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

ABLATION THERAPY; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CHILD; CLINICAL FEATURE; DELAYED RISK STRATIFICATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT; PATIENT CODING; PRACTICE GUIDELINE; PREDICTION; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK; RISK ASSESSMENT; THYROID CANCER; THYROIDECTOMY; TREATMENT RESPONSE; VARIANCE; CANCER CLASSIFICATION; CANCER SURGERY; CONTROLLED STUDY; REVIEW; RISK FACTOR; TUMOR ABLATION; TUMOR DIFFERENTIATION; ADOLESCENT; ADULT; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; THYROID TUMOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 80051678492     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0466     Document Type: Article

References (13)

1. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR & Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993 114 1050-1057.
2. Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, Mayer M, Sylvester RJ & van Glabbeke M. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. European Journal of Cancer 1979 15 1033-1041. (Pubitemid 9254743)
3. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP & Parmentier C. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985 55 794-804. (doi:10.1002/1097-0142(19850215)55:4⟨794::AID- CNCR2820550418⟩3.0.CO;2-Z)
4. DeGroot LJ, Kaplan EL, McCormick M& Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1990 71 414-424. (doi:10.1210/jcem-71-2-414)
5. Mazzaferri EL & Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 1994 97 418-428. (doi:10.1016/0002-9343(94)90321-2)
6. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG & Morrow M. AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors, 6th edn. DRS York: Springer-Verlag, 2002.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL & Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009.0110)
8. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & Wiersinga W & European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787-803. (doi:10.1530/eje.1.02158)
9. Tuttle RM. Risk-adapted management of thyroid cancer. Endocrine Practice 2008 14 764-774.
10. Tuttle RM & Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinology and Metabolism Clinics of North America 2008 37 419-435. (doi:10.1016/j.ecl.2008.02.008)
11. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA & Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the DRS American Thyroid Association staging system. Thyroid 2010 20 1341-1349. (doi:10.1089/thy.2010.0178)
12. Galen RS.Application of the predictive value model in the analysis of test effectiveness. Clinics in Laboratory Medicine 1982 2 685-699. (Pubitemid 13074757)
13. Verburg FA, Stokkel MP, Düren C, Verkooijen RB, Mäder U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C & Luster M. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 276-283. (doi:10.1007/s00259-009-1315-6)